A catalog of numerical centrosome defects in epithelial ovarian cancers.
centrosome number alterations
centrosomes
ovarian cancers
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
07 09 2022
07 09 2022
Historique:
revised:
21
07
2022
received:
03
01
2022
accepted:
21
07
2022
entrez:
7
9
2022
pubmed:
8
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Centrosome amplification, the presence of more than two centrosomes in a cell is a common feature of most human cancer cell lines. However, little is known about centrosome numbers in human cancers and whether amplification or other numerical aberrations are frequently present. To address this question, we have analyzed a large cohort of primary human epithelial ovarian cancers (EOCs) from 100 patients. We found that rigorous quantitation of centrosome number in tumor samples was extremely challenging due to tumor heterogeneity and extensive tissue disorganization. Interestingly, even if centrosome clusters could be identified, the incidence of centrosome amplification was not comparable to what has been described in cultured cancer cells. Surprisingly, centrosome loss events where a few or many nuclei were not associated with centrosomes were clearly noticed and overall more frequent than centrosome amplification. Our findings highlight the difficulty of characterizing centrosome numbers in human tumors, while revealing a novel paradigm of centrosome number defects in EOCs.
Identifiants
pubmed: 36069081
doi: 10.15252/emmm.202215670
pmc: PMC9449595
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15670Informations de copyright
© 2022 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Curr Biol. 2015 Mar 30;25(7):879-89
pubmed: 25772448
J Cell Biol. 2010 Nov 15;191(4):721-9
pubmed: 21059850
Nat Cell Biol. 2016 Jan;18(1):100-10
pubmed: 26595384
EMBO J. 2018 May 2;37(9):
pubmed: 29567643
Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63
pubmed: 17505520
Open Biol. 2015 Dec;5(12):150209
pubmed: 26701933
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
Cancer Discov. 2011 Jul;1(2):144-57
pubmed: 22303516
Oncogene. 2020 Jan;39(2):399-413
pubmed: 31477840
Cancer Res. 2012 Jun 1;72(11):2701-4
pubmed: 22593197
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Biol Open. 2012 Oct 15;1(10):965-76
pubmed: 23213374
Nature. 2014 Jun 5;510(7503):167-71
pubmed: 24739973
Mol Biol Cell. 2012 May;23(10):1838-45
pubmed: 22456511
Science. 2015 Jun 5;348(6239):1155-60
pubmed: 25931445
Dev Cell. 2007 Aug;13(2):190-202
pubmed: 17681131
Nat Struct Mol Biol. 2014 Aug;21(8):696-703
pubmed: 24997597
PLoS One. 2009 Aug 10;4(8):e6564
pubmed: 19668340
Nature. 2009 Jul 9;460(7252):278-82
pubmed: 19506557
Methods Mol Biol. 2013;1046:133-44
pubmed: 23868586
J Cell Sci. 2008 Jan;121 Suppl 1:1-84
pubmed: 18089652
Cancers (Basel). 2018 Nov 15;10(11):
pubmed: 30445726
Oncology (Williston Park). 2016 Feb;30(2):166-76
pubmed: 26892153
Nat Rev Mol Cell Biol. 2015 Oct;16(10):611-24
pubmed: 26373263
Nat Commun. 2018 Mar 28;9(1):1258
pubmed: 29593297
Dev Cell. 2018 Nov 19;47(4):409-424.e9
pubmed: 30458137
Science. 2012 Jan 27;335(6067):422-6
pubmed: 22282802
Oncogene. 2016 May;35(21):2711-22
pubmed: 26364601
Trends Cell Biol. 2009 Jul;19(7):334-46
pubmed: 19570677
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Cell. 2008 Jun 13;133(6):1032-42
pubmed: 18555779
Dev Cell. 2003 Jul;5(1):113-25
pubmed: 12852856
J Cell Sci. 2013 Jul 15;126(Pt 14):3223-33
pubmed: 23641073
J Cell Biol. 2015 Jul 6;210(1):63-77
pubmed: 26150389
Dev Cell. 2017 Feb 6;40(3):217-218
pubmed: 28171744
Nat Commun. 2018 Mar 7;9(1):1036
pubmed: 29515130
Dev Cell. 2019 Jul 1;50(1):11-24.e10
pubmed: 31130353
Curr Biol. 2019 Sep 23;29(18):2993-3005.e9
pubmed: 31495584
Curr Opin Struct Biol. 2021 Feb;66:74-82
pubmed: 33186811
Dev Cell. 2017 Feb 6;40(3):313-322.e5
pubmed: 28132847